Aurinia Pharmaceuticals Inc. (AUP.TO) (TSE:AUP) (NASDAQ:AUPH) – Equities researchers at Cantor Fitzgerald cut their FY2021 earnings estimates for Aurinia Pharmaceuticals Inc. (AUP.TO) in a research note issued to investors on Tuesday, January 12th. Cantor Fitzgerald analyst A. Young now expects that the company will post earnings of ($1.38) per share for the year, down from their prior estimate of ($1.03).
Aurinia Pharmaceuticals Inc. (AUP.TO) (TSE:AUP) (NASDAQ:AUPH) last released its quarterly earnings results on Tuesday, November 10th. The company reported C($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.29) by C($0.08). The firm had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.08 million.
Aurinia Pharmaceuticals Inc. (AUP.TO) stock opened at C$17.66 on Thursday. The firm has a 50 day moving average of C$18.09 and a 200 day moving average of C$19.05. The firm has a market capitalization of C$2.24 billion and a price-to-earnings ratio of -12.55. Aurinia Pharmaceuticals Inc. has a 12-month low of C$0.02 and a 12-month high of C$27.10. The company has a current ratio of 17.23, a quick ratio of 16.46 and a debt-to-equity ratio of 2.08.
Aurinia Pharmaceuticals Inc. (AUP.TO) Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Read More: What is the definition of market timing?
Receive News & Ratings for Aurinia Pharmaceuticals Inc. (AUP.TO) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. (AUP.TO) and related companies with MarketBeat.com's FREE daily email newsletter.